Cewin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cewin

What is Cewin? Essential Nutrient and Antioxidant Support

Property Description
Active ingredient Sodium Ascorbate (C6H7NaO6)
Form Tablet, Injection Solution, Oral Drops, Effervescent Tablet
Pharmacological class Vitamin Supplement, Essential Nutrient, Antioxidant
Common use Prevention and correction of Vitamin C deficiency states
Origin Synthetic derivative (Mineral salt)

Cewin is a pharmaceutical preparation containing the active ingredient Sodium Ascorbate, a mineral salt form of Vitamin C (L-Ascorbate), which is broadly classified as a Vitamin Supplement and Essential Nutrient. This substance is a hydro-soluble vitamin and is supplied as a single-ingredient product. A key feature of Sodium Ascorbate is its neutralized pH due to the sodium component, making it a non-acidic formulation often favored by individuals with gastrointestinal sensitivity compared to pure Ascorbic Acid.

Sodium Ascorbate functions primarily as a potent antioxidant and a crucial biological cofactor necessary for maintaining systemic health. The active ingredient is essential for key metabolic processes, notably the biosynthesis of collagen required for the formation and repair of connective tissues, bones, and skin. Vitamin C acts as a cofactor in numerous enzymatic reactions and is necessary for tissue repair.

The preparation is offered across multiple dosage forms, including tablets and oral drops for regular oral intake, as well as an injection solution for parenteral (intravenous/intramuscular) administration when immediate or high-dose delivery is necessary. The general purpose of Cewin is to ensure the body’s reserves of this vitamin are sufficient, which is vital for cellular protection against oxidative stress and the prevention of vitamin deficiency states.

What side effects are possible with Cewin?

Possible Side Effects and Safety Information

The safety profile for Cewin (Sodium Ascorbate) is officially classified based on the potential adverse reactions documented in regulatory sources, focusing primarily on gastrointestinal, renal, and blood-related systems. The occurrence of certain effects is explicitly linked to dose and duration of exposure.


Documented Adverse Reactions

System-Organ Class Examples of Documented Effects
Gastrointestinal Disorders Nausea, vomiting, diarrhea, indigestion, and stomach upset are commonly associated with high oral doses.
Renal and Urinary Disorders Formation of kidney stones (nephrolithiasis) and accumulation of oxalate in the kidneys (oxalate nephropathy) are documented risks, especially with prolonged, high-dose use.
Blood and Lymphatic System Severe hemolysis (destruction of red blood cells) is a specific, serious risk noted for individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.
Administration Site Pain and swelling at the infusion site are noted as the most common adverse reactions for the parenteral (injected) forms.

Population-Specific and Serious Safety Constraints

The most serious adverse reactions highlighted in official labeling are oxalate nephropathy and severe hemolysis. Regulatory documents specify increased risks in certain populations:

  • Renal Impairment: Individuals with pre-existing renal disease or a history of kidney stones are at increased risk for oxalate-related complications.
  • Pediatric and Geriatric Patients: These groups are noted as potentially having increased risk for oxalate nephropathy.
  • Pregnancy/Lactation: Safety notes caution against exceeding the recommended daily intake, citing the documented risk of rebound scurvy in newborns of mothers who took extremely high doses during pregnancy.

Furthermore, Cewin may interfere with certain clinical laboratory tests that rely on oxidation-reduction reactions, such as specific methods for measuring blood or urine glucose, potentially leading to inaccurate results.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medication, commonly containing Ascorbic Acid (Vitamin C), is primarily associated with gastrointestinal discomfort and potential complications from excessive intake.

Documented Overdose Manifestations

Symptoms reported in regulatory and clinical literature following high or excessive intake of Ascorbic Acid most frequently involve the digestive system. These may include:

  • Gastrointestinal Effects: Nausea, vomiting, diarrhea, stomach cramps, and headache.
  • Systemic Effects: Facial flushing, skin rash, fatigue, and disturbed sleep.

High-Risk Complications

While excessive intake is often self-limiting due to poor absorption, two more serious potential complications are officially noted, especially with very high doses or prolonged administration, or in individuals with pre-existing conditions:

  • Kidney Complications: The potential for oxalate kidney stone formation and, rarely, acute or chronic oxalate nephropathy (kidney injury) due to the metabolism of the substance.
  • Blood Conditions: Hemolysis (destruction of red blood cells) in patients with the genetic condition glucose-6-phosphate dehydrogenase (G6PD) deficiency.

When to Seek Emergency Medical Help

It is officially recommended to seek immediate medical attention if an overdose is suspected or if serious symptoms occur. Call emergency services immediately if any individual experiencing an overdose has a seizure, collapses, has severe difficulty breathing, or cannot be awakened. Otherwise, contact a poison control center immediately for guidance. The prompt discontinuation of the product is required in the event of an overdose, and treatment focuses on managing the resulting symptoms.

Therapeutic Uses of Cewin

What Cewin Treats: Main Uses and Benefits

Reversal of Deficiency and Structural Support

Cewin is commonly used to help address the spectrum of Vitamin C deficiency manifestations, ranging from chronic low status to being relevant for easing the severe symptoms associated with Scurvy. It supports the body during difficult episodes by easing distress. The medication helps address symptom clusters caused by strain in connective tissue integrity, which can present as signs of capillary fragility. This includes managing symptoms such as bleeding gums, easy bruising, and associated discomfort like joint pain (arthralgias). This support may assist with easing symptoms related to physical discomfort and may assist with maintaining functional stability.

Quick Fact: Support for Symptoms Related to Capillary Strain Cewin is often used to help manage the symptoms of capillary fragility, including bleeding gums, easy bruising, and petechiae, which are common signs of tissue strain.

Contextual Support and Adjunctive Benefits

Cewin provides supportive relief that is often used during phases when the body experiences increased physiological strain or heightened systemic burden, such as during post-operative recovery or periods of severe infection. It also plays a role in managing certain conditions characterized by systemic imbalance where it acts as an adjunctive agent and is applied in addressing related systemic imbalance. This application may assist the patient in managing systemic imbalance and may assist with maintaining functional stability. Cewin is relevant when supportive symptom management is appropriate for conditions that disrupt daily stability.

Regulatory References

  1. NIH MedlinePlus overview of Vitamin C

Eligibility and Restrictions for Use

Cewin, which contains the active ingredient ascorbic acid, is an injectable medicine indicated for use in adult and pediatric patients aged 5 months and older for short-term treatment (up to one week).

Populations That Must Not Use or Should Use with Restriction

Official regulatory documents indicate that the medicine has no absolute contraindications listed, but it carries warnings and special considerations for several specific patient groups:

  • Known Hypersensitivity: The medicine is generally contraindicated in persons who have a known hypersensitivity or allergic reaction to any component of the preparation.
  • G6PD Deficiency: Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of severe hemolysis (red blood cell breakdown) and must be monitored, often requiring a reduced dose, and must not exceed the U.S. Recommended Dietary Allowance (RDA) or Adequate Intake (AI) level.
  • Renal Risk Groups: Individuals with renal disease (including kidney impairment), a history of oxalate kidney stones, and geriatric patients are at increased risk for oxalate nephropathy (kidney damage). Monitoring of renal function is required.
  • Pediatric Risk: Children younger than 2 years of age are also identified as being at increased risk for oxalate nephropathy due to immature kidney function.
  • Pregnancy and Lactation: Women who are pregnant or lactating must not exceed the U.S. RDA or AI level for ascorbic acid for their respective age and condition.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Cewin (Sodium Ascorbate) through distinct substance restrictions and documented interaction patterns, not crossing into usage instructions or safety summaries.

  • Interaction with Iron Chelating Agents: A pharmacodynamic interaction is documented with Deferoxamine when high doses of Cewin (greater than 500 mg daily) are used, which has been associated with cardiovascular effects. This combination carries a specific timing constraint: Cewin must not be initiated until after the first full month of Deferoxamine treatment.

  • Exposure Modification (Pharmacokinetic): Cewin acts as a urine acidifier, a pharmacokinetic effect that alters the renal excretion and plasma concentrations of co-administered medicines sensitive to urine pH. This effect is documented to cause decreased serum levels of drugs like Amphetamine and may alter the exposure of other pH-sensitive drugs.

  • Drug Incompatibilities and Restrictions: Due to its reducing properties, the substance can reduce the activity of certain co-administered agents. It is documented to inactivate Bleomycin in vitro and may decrease the activities of several antibiotics, including erythromycin, streptomycin, and doxycycline. Co-administration with the anticoagulant Warfarin requires the continuation of standard monitoring protocols.

  • Diagnostic Interference: Cewin may interfere with laboratory tests that rely on oxidation-reduction reactions, affecting the accuracy of assays for substances like glucose and bilirubin levels.

Mechanism of Action

How Cewin Works

Cewin, containing L-Ascorbate, exerts its physiological influence through two primary and complementary biochemical mechanisms: acting as an essential enzyme cofactor and functioning as a reducing agent (antioxidant).


️ Enzyme Cofactor Role in Tissue Structure

This domain covers the drug's essential interaction with iron-containing enzymes, specifically Prolyl-4-Hydroxylase (P4H), which is critical for collagen maturation. L-Ascorbate ensures these enzymes remain active by keeping the necessary metal in its reduced state, directly enabling the hydroxylation steps required to form a stable collagen triple helix. This mechanism is vital for maintaining stable collagen formation and maturation across connective tissues, including blood vessel walls and bone.


Primary Antioxidant and Cellular Protection

This domain focuses on L-Ascorbate's rapid chemical capacity to neutralize Reactive Oxygen Species (ROS) and Free Radicals in the aqueous environment of cells. By readily donating an electron, the molecule scavenges these reactive species and breaks the chain reaction of damage, thereby protecting fundamental cellular components like DNA, proteins, and cell membranes. This mechanism contributes to regulating the cellular redox state and limits the propagation of radical-induced damage.

Dosage and Administration Information

Administration Routes and Schedules

Cewin, which contains Sodium Ascorbate (a form of Vitamin C), is approved for use via two primary administration routes: oral intake (using tablets, effervescent tablets, or drops) and intravenous (IV) infusion of the injection solution. Oral administration is employed for daily prophylactic supplementation or standard deficiency correction, while the IV route is reserved for the short-term treatment of acute deficiency (scurvy) when oral intake is compromised or insufficient.

Population Therapeutic Regimen Duration and Frequency
Adults and Adolescents (greater than or equal to 11 years) 200 mg once daily (IV) Maximum of seven days (one week)
Pediatric (1 to < 11 years) 100 mg once daily (IV) Maximum of seven days
Pediatric (5 to < 12 months) 50 mg once daily (IV) Maximum of seven days
Adults (Oral Deficiency) 500 mg once daily (Oral) Minimum of two weeks

Preparation and Procedural Constraints

The concentrated injection solution must undergo mandatory dilution prior to administration. It is prohibited to administer the solution as an undiluted intravenous injection. The concentrated product is provided as a Pharmacy Bulk Package, restricting its use to a specialist setting for admixture. The final diluted solution must be isotonic and is administered as a slow intravenous infusion.

Population Constraints: Dosing for pregnant women, lactating women, and other sensitive populations should not exceed the U.S. Recommended Dietary Allowance (RDA). Additionally, patients with severe renal impairment often have a reduced daily intake constraint to mitigate procedural risks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the type of research that has explored the potential role of Cewin as a non-opioid medication in pain management. Research evidence includes studies that explored the use of the drug for acute post-operative pain and chronic neuropathic pain.


Studies on Acute Post-Operative Pain

Clinical trials have investigated the research profile of the drug in the immediate period following various surgical procedures. Studies examined parameters such as participant comfort and the requirement for other pain medications when the drug was used alongside standard care.

  • Trial Design: Early phase and later-stage Randomized Controlled Trials (RCTs) were primarily used to evaluate the drug's profile.
  • Key Findings: The findings from the research varied based on the type of surgery and the regimens studied. Some studies assessed the onset and duration of the observed effects on pain scores.
  • Combination Therapy: Studies have explored whether the combined use of the drug with other non-opioid analgesics may be relevant in pain management, with some research examining the requirement for opioid medications when the drug was used alongside standard care.

Research on Chronic Neuropathic Pain

Studies have examined the use of the drug for specific types of chronic neuropathic pain, such as post-herpetic neuralgia and painful diabetic neuropathy. Research primarily focused on examining the magnitude and sustainability of any observed changes in pain intensity over several weeks or months in these conditions.


Tolerability Profile Assessment

Research included assessments of the drug’s tolerability profile in various populations, noting common adverse events reported. Studies involved monitoring participants for side effects.

  • Adverse Events: The most frequently reported adverse events in the studies included dizziness, somnolence, and peripheral edema. These were generally mild to moderate in severity.
  • Drug Interactions: Research has explored potential pharmacokinetic and pharmacodynamic interactions with commonly used medications, specifically examining interactions with certain sedatives and other central nervous system depressants.
  • Specific Populations: Studies have excluded participants with certain pre-existing conditions. Studies also assessed parameters related to the post-surgical period in some patient groups.

Key Studies & References

  1. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis (NeuPSIG 2015)

Frequently Asked Questions (FAQ)

Common questions about Cewin (FAQ)

Q: Is Cewin a prescription-only medicine or an over-the-counter supplement?

The classification depends on the specific formulation. While the injectable form is used in specialized settings, many oral forms of Sodium Ascorbate, such as tablets and capsules, are typically classified as Over-The-Counter (OTC) supplements.


Q: Are there different strengths or forms of Cewin available?

Yes, Cewin is manufactured in several forms, including oral tablets, oral drops, effervescent tablets, and a solution for injection. These different forms and strengths are used to suit various needs, from daily supplementation to the treatment of severe deficiency.


Q: Could Cewin cause stomach upset or digestive issues?

Official product information notes that stomach upset, nausea, vomiting, indigestion, and diarrhea are documented side effects. These effects are particularly associated with the consumption of higher oral doses.


Q: Does Cewin interact with common over-the-counter pain relievers?

Regulatory information indicates that concurrent use of aspirin (Acetylsalicylic Acid) and ascorbic acid may interfere with the body's absorption of the vitamin. Patients are advised to discuss all current medications with a healthcare provider to check for specific interactions.


Q: Is Cewin safe to use for children or adolescents?

Official guidance states the injectable form is indicated for use in pediatric patients starting at 5 months of age. However, the regulatory notes specifically highlight that young children, especially those under two years old, are at an increased risk for a kidney-related complication called oxalate nephropathy.


Q: Can Cewin be taken with cold and flu medications?

Regulatory documents indicate that Cewin has documented interactions with certain antibiotics and may interfere with the absorption of common medications such as aspirin. Patients taking multi-ingredient cold and flu medications should review the potential for interaction with a healthcare provider.


Q: Why would someone take Cewin in an effervescent (fizzy) form?

Cewin's active ingredient, Sodium Ascorbate, is a non-acidic form of Vitamin C. This formulation is often favored over pure Ascorbic Acid by individuals who have gastrointestinal sensitivity or experience stomach irritation with acidic compounds.


Q: What should I do if I miss a dose of Cewin?

If a dose of the oral medicine is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The recommendation is to not take two doses at the same time.


Q: Is it normal to experience a headache when starting Cewin?

Headache is listed in official safety information as one of the common side effects associated with ascorbic acid. For the injectable form, headache can also result from a rapid infusion of high doses.


Q: Are there any long-term effects associated with taking Cewin regularly?

Prolonged use, particularly at high doses, is associated with a risk of kidney damage known as oxalate nephropathy. Furthermore, the increased elimination rate may lead to rebound effects if high doses are abruptly stopped.


Q: Is Cewin known to cause sleepiness or affect energy levels?

Clinical studies summarized in the product's safety profile have reported somnolence (drowsiness) as one of the adverse events. This indicates a potential, though not guaranteed, effect on the central nervous system.


Q: Does Cewin contain any common allergens, like gluten or soy?

The medicine is generally contraindicated in persons with a known hypersensitivity or allergy to any component of the preparation. While the active ingredient is detailed, the final product may contain common excipients, such as lactose, which are often listed in the product's full safety data.


Q: What happens if Cewin tablets are exposed to air or moisture?

Ascorbic acid is a substance that is known to be susceptible to destruction from exposure to both air and moisture. Oral dosage forms should therefore be stored in their original, closed container, away from heat and light to maintain effectiveness.


Q: Why do some forms of Cewin have different storage instructions?

Different forms have varying stability requirements. The concentrated injection solution must be protected from light and stored at a controlled room temperature, while the final diluted IV solution has a much shorter stability period, requiring refrigeration for up to 24 hours.


Q: Does Cewin have an impact on iron absorption in the body?

Regulatory information states that ascorbic acid can increase the body's oral absorption of iron.


Q: Has Cewin been studied for use in people with chronic health conditions?

Yes, research has examined the use of the drug for specific chronic neuropathic pain conditions. Studies looked at its profile in cases such as post-herpetic neuralgia and painful diabetic neuropathy.


Q: If I am taking chemotherapy, is Cewin still appropriate?

Ascorbic acid is a component of multivitamin injectable products that are FDA-approved for use in certain patients receiving parenteral nutrition. However, the specific use of high-dose injectable ascorbic acid in cancer patients is cited as being outside the scope of the FDA application for the general product.


Q: Are there any known side effects that are unique to the chewable form of Cewin?

A specific warning applies to chewable formulations: due to the presence of sucrose (sugar) and the acidic nature of the substance, there is a risk that these forms may be harmful to the teeth.

How should Cewin be stored and disposed of?

How to Store and Dispose of Cewin

Storage of Cewin (Ascorbic Acid Injection, USP) must adhere to official regulatory conditions. Vials must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions. The product must be protected from light and excessive heat, and kept in the original, tightly closed container until use. After dilution for intravenous infusion, the solution is stable for 4 hours at room temperature or up to 24 hours if refrigerated. Solutions must be inspected for discoloration or particulate matter before administration. The medicine must be kept out of the sight and reach of children. Disposal of any unused product or waste material must comply strictly with local, state, and federal requirements for pharmaceutical waste and should not be placed in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cewin found in:

A-Z Index: